Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma

#1775

Introduction: Gastric poorly differentiated neuroendocrine carcinoma (G-PDNEC) is rare and aggressive. Patients often present with distant metastases at initial diagnosis.

Aim(s): To investigate the expression of SSTR2A and some key components of the AKT/mTOR signaling pathwayin G-PDNEC for potential target therapy.

Materials and methods: We evaluated 127 G-PDNECs by immunohistochemistry. SSTR2A membranous positivity was graded from 0-3+. TSC2, P70S6K, and p4EBP1 cytoplasmic staining, p-mTOR nuclear staining, and pAKT,PTEN nuclear/cytoplasmic staining were scored as positive if >5% of cells stained.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: JI Y

Authors: Ji Y, Xie Y, Chen K, Zeng H, Sun Y,

Keywords: gastric, neuroendocrine carcinoma, mTOR pathway, SSTR, targeted therapies,